Last reviewed 2026-05-30 · How we verify

Beta-Adrenergic Antagonist

Roswell Park Cancer Institute · Phase 1 active Small molecule ✓ Verified May 2026 Quality 10/100

Beta-Adrenergic Antagonist is a Small molecule drug developed by Roswell Park Cancer Institute. It is currently in Phase 1 development. Also known as: Beta Blocker, Beta-Adrenergic Blocking Agent, Beta-Blockers.

Beta-Adrenergic Antagonists are used to treat various conditions, including Glaucoma, Cardiovascular Disease, Heart Failure, and Atrial Fibrillation, as indicated by ClinicalTrials.gov. They are a type of medication, classified as Beta Blockers, which are also studied in combination with other interventions such as Prostaglandin Analogue-containing IOP-lowering therapy.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Beta-Adrenergic Antagonist
Also known as	Beta Blocker, Beta-Adrenergic Blocking Agent, Beta-Blockers
Sponsor	Roswell Park Cancer Institute
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Hypertension
Dyspnoea
Dizziness
Cardiac failure
Viral upper respiratory tract infection
Hypotension
Hyperkalaemia
Back pain
Arthralgia
Cough
Upper respiratory tract infection
Pain in extremity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Beta-Adrenergic Antagonist CI brief — competitive landscape report
Beta-Adrenergic Antagonist updates RSS · CI watch RSS
Roswell Park Cancer Institute portfolio CI

Frequently asked questions about Beta-Adrenergic Antagonist

What is Beta-Adrenergic Antagonist?

Beta-Adrenergic Antagonist is a Small molecule drug developed by Roswell Park Cancer Institute.

Who makes Beta-Adrenergic Antagonist?

Beta-Adrenergic Antagonist is developed by Roswell Park Cancer Institute (see full Roswell Park Cancer Institute pipeline at /company/roswell-park-cancer-institute).

Is Beta-Adrenergic Antagonist also known as anything else?

Beta-Adrenergic Antagonist is also known as Beta Blocker, Beta-Adrenergic Blocking Agent, Beta-Blockers.

What development phase is Beta-Adrenergic Antagonist in?

Beta-Adrenergic Antagonist is in Phase 1.

What are the side effects of Beta-Adrenergic Antagonist?

Common side effects of Beta-Adrenergic Antagonist include Hypertension, Dyspnoea, Dizziness, Cardiac failure, Viral upper respiratory tract infection, Hypotension.

Manufacturer: Roswell Park Cancer Institute — full pipeline
Also known as: Beta Blocker, Beta-Adrenergic Blocking Agent, Beta-Blockers

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing